Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01513733 · ClinicalTrials.gov registry record · Phase 1
The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer
A Phase 1 study, sponsored by Andrew J. Armstrong, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01513733: Completed Phase 1 study, sponsored by Andrew J. Armstrong, MD.
NCT01513733 is a Phase 1 study that has completed, run by Andrew J. Armstrong, MD. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01513733, a Phase 1 study, has completed, sponsored by Andrew J. Armstrong, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The standard of care for men with metastatic CRPC in 2010 following progression on docetaxel is cabazitaxel or abiraterone acetate/prednisone. Based on results from two other studies, cabazitaxel and prednisone has become a standard second line chemotherapy regimen and becomes the backbone upon which to improve upon. Thus, the primary objective of this study is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).
Primary Outcome
The primary objective is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).
Interventions
- DRUG tasquinimod
- DRUG tasquinimod 0.25 mg; 0.5 mg
- DRUG tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-01 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
What the finished NCT01513733 record still lists
NCT01513733 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 3 interventions - of which tasquinimod is the first listed.
NCT01513733 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01513733 about?
NCT01513733 is a clinical study titled "The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer". The standard of care for men with metastatic CRPC in 2010 following progression on docetaxel is cabazitaxel or abiraterone acetate/prednisone. Based on results from two other studies, cabazitaxel and prednisone has become a standard second line chemotherapy regimen and becomes the backbone upon whic...
What is the current status of trial NCT01513733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2012-01. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01513733?
The interventions under investigation include: tasquinimod (DRUG), tasquinimod 0.25 mg; 0.5 mg (DRUG), tasquinimod 0.25 mg; 0.5 mg; 1.0 mg (DRUG).
Who is sponsoring clinical trial NCT01513733?
This trial is sponsored by Andrew J. Armstrong, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01513733's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia